Research Identifies New Molecular Subtypes and Therapeutic Targets for Small Cell Lung Cancer
Researchers identified three distinct molecular phenotypes of small cell lung cancer that could help stratify patients for targeted therapy. Only patients with ANXA1Low infiltrated phenotype derived significant survival benefit from chemotherapy plus immune checkpoint inhibitors. Separate research found that targeting epigenetic regulators like PRC2 and G9a/GLP could enhance treatment efficacy.
Researchers have identified three distinct molecular phenotypes of small cell lung cancer that could help stratify patients for targeted therapy and immunotherapy. The study found that only patients with a specific ANXA1Low infiltrated phenotype derived significant survival benefit from chemotherapy plus immune checkpoint inhibitors, while an ANXA1High subset within the immune-rich infiltrated phenotype showed resistance to these treatments.
The three phenotypes were termed proliferative, iNotch, and infiltrated phenotypes, characterized by high proliferation, inhibitory Notch signaling, and immune-rich microenvironments, respectively. These phenotypes were reproducible across three bulk independent datasets. Further intercellular communication analysis of single-cell RNA sequencing data revealed that a subset with high ANXA1 expression in the infiltrated phenotype suppressed CD8+ T cells via M2 macrophage polarization.
In a separate study exploring epigenetic targets, researchers found that conditional deletion of Eed, a core structural component of Polycomb repressive complex 2 (PRC2), prevented tumor formation in an autochthonous SCLC model. In contrast, enzymatic inhibition of EZH2 had no impact on tumor growth but significantly altered the PRC2 interactome, unveiling novel targets for drug development. The findings revealed that prolonged EZH2 inhibition sensitized neuroendocrine cancer cells to G9a/GLP inhibition.
Transcriptomic analysis revealed that the drug combination of EZH2 and G9a/GLP inhibitors triggered an oxidative stress response by modulating the expression of cellular oxidases, an effect that could be reversed by antioxidant treatment. These results underscore the critical role of PRC2's structural functions in SCLC and identify promising drug combinations to enhance the efficacy of EZH2 inhibitors.
Small cell lung cancer is an aggressive neuroendocrine malignancy that exhibits high intertumoral heterogeneity and limited treatment options. Immune checkpoint inhibitors provide only modest benefits for SCLC, underscoring the need for clinically actionable phenotypes. The identification of molecular subtypes with unique therapeutic vulnerabilities offers new strategies to enhance treatment efficacy for this challenging cancer.